Baseline 18 F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy
Cancer Biotherapy and Radiopharmaceuticals · 2025
DOI: 10.1089/cbr.2024.0115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Fenglian Jing und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Fluorodeoxyglucose F18, Antineoplastic Combined Chemotherapy Protocols, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to predict therapeutic efficacy among diffuse large B-cell lymphoma (DLBCL) after R-CHOP (-like) therapy using baseline 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) radiomics.
Methods
A total of 239 patients with DLBCL were enrolled in this study, with 82 patients having refractory/relapsed disease. The radiomics signatures were developed using a stacking ensemble approach. The efficacy of the radiomics signatures, the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI), conventional PET parameters model, and their combinations in assessing refractory/relapse risk were evaluated using receiver operating characteristic (ROC) curves, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and decision curve analysis.
Results
The stacking model, along with the integrated model that combines stacking with the NCCN-IPI and SD max (the distance between the two lesions farthest apart, normalized to the patient's body surface area), showed remarkable predictive capabilities with a high area under the curve (AUC), sensitivity, specificity, PPV, NPV, accuracy, and significant net benefit of the AUC (NB-AUC). Although no significant differences were observed between the combined and stacking models in terms of the AUC in either the training cohort (AUC: 0.992 vs. 0.985, p = 0.139) or the testing cohort (AUC: 0.768 vs. 0.781, p = 0.668), the integrated model exhibited higher values for sensitivity, PPV, NPV, accuracy, and NB-AUC than the stacking model.
Conclusion
Baseline PET radiomics could predict therapeutic efficacy in DLBCL after R-CHOP (-like) therapy, with improved predictive performance when incorporating clinical features and SD max .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, People's Republic of China.
- Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, People's Republic of China.
ORCID-Profile: Xinming Zhao
Zitieren
APA
Jing, F., Zhang, X., Liu, Y., Chen, X., Zhao, X., Chen, X., Yuan, H., Dai, M., Wang, N., Han, J., & Zhang, J. (2025). Baseline 18 F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0115
Vancouver
Jing F, Zhang X, Liu Y, Chen X, Zhao X, Chen X, et al. Baseline 18 F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2024.0115
BibTeX
@article{Jing2025,
author = {Jing, Fenglian and Zhang, Xinchao and Liu, Yunuan and Chen, Xiaolin and Zhao, Xinming and Chen, Xiaoshan and Yuan, Huiqing and Dai, Meng and Wang, Na and Han, Jingya and Zhang, Jingmian},
title = {Baseline 18 F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
doi = {10.1089/cbr.2024.0115}
}
EUVIMED